Table 2 Cox proportional-hazards regression models for overall survival, prostate cancer-specific mortality and biochemical recurrence (model 1), adjusted by propensity scores (model 2), and Gleason score (model 3).
Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
Overall Survival | ||||||
Radical prostatectomy | Ref | Ref | Ref | |||
Brachytherapy | 1.67 (1.10—2.52) | 0.015 | 1.32 (0.75 – 2.33) | 0.342 | 1.36 (0.77—2.42) | 0.292 |
External radiotherapy | 1.98 (1.28—3.06) | 0.002 | 1.40 (0.78—2.51) | 0.259 | 1.44 (0.80—2.59) | 0.222 |
Propensity scorea | ||||||
Propensity scoreb | 1.50 (0.64 – 3.52) | 0.347 | 1.44 (0.57—3.61) | 0.442 | ||
Gleason score | 2.36 (0.96 – 5.78) | 0.061 | 2.33 (0.95—5.74) | 0.066 | ||
≤ 6 | Ref | |||||
7 | 0.96 (0.60—1.55) | 0.882 | ||||
Prostate Cancer-Specific Mortalitya | ||||||
Radical prostatectomy | Ref | Ref | Ref | |||
Brachytherapy | 5.55 (0.71—43.24) | 0.100 | 4.45 (0.69 – 28.71) | 0.120 | 4.41 (0.69—28.29) | 0.120 |
External radiotherapy | 12.23 (1.61—92.95) | 0.016 | 9.46 (1.55 – 57.79) | 0.015 | 9.37 (1.53—57.21) | 0.015 |
Propensity scorea | 1.54 (0.15 – 16.05) | 0.720 | 1.58 (0.17—14.45) | 0.690 | ||
Propensity scoreb | 1.85 (0.26 – 12.98) | 0.540 | 1.85 (0.27—12.52) | 0.530 | ||
Gleason score | ||||||
≤ 6 | Ref | |||||
7 | 1.04 (0.31—3.47) | 0.960 | ||||
Biochemical recurrencea | ||||||
Radical prostatectomy | Ref | Ref | Ref | |||
Brachytherapy | 1.14 (0.78—1.67) | 0.490 | 1.89 (1.20 – 2.95) | 0.006 | 1.93 (1.23—3.03) | 0.004 |
External radiotherapy | 1.76 (1.20—2.59) | 0.004 | 2.50 (1.60 – 3.89) | < 0.001 | 2.56 (1.64—3.98) | < 0.001 |
Propensity scorea | 0.34 (0.17 – 0.67) | 0.002 | 0.36 (0.17—0.75) | 0.006 | ||
Propensity scoreb | 0.52 (0.26 – 1.05) | 0.067 | 0.52 (0.26—1.06) | 0.074 | ||
Gleason score | ||||||
≤ 6 | Ref | |||||
7 | 1.05 (0.86—1.29) | 0.610 | ||||